Browse history interactively

Page 1

Page 1Revision 1

Page 2

Page 2Revision 2

← Previous editContent deleted Content addedVisualWikitext

Revision as of 22:56, 9 March 2011 editCheMoBot (talk | contribs)Bots141,565 edits Updating {{drugbox}} (no changed fields - added verified revid - updated 'UNII_Ref', 'ChemSpiderID_Ref', 'StdInChI_Ref', 'StdInChIKey_Ref', 'ChEMBL_Ref', 'KEGG_Ref') per Chem/Drugbox validation (← Previous edit		Latest revision as of 18:55, 4 August 2024 edit undoKku (talk | contribs)Extended confirmed users115,685 editsm link acrolein
(57 intermediate revisions by 39 users not shown)
Line 1:		Line 1:
			{{Short description|Chemical compound}}
	{{Orphan|date=February 2009}}
			{{distinguish|Pancreastatin}}
			{{Drugbox
			| Watchedfields = changed
		⚫	| verifiedrevid = 418035302
		⚫	| IUPAC_name = (1''R'',2''S'',3''S'',4''S'',4a''R'',11b''R'')-1,2,3,4,7-pentahydroxy-2,3,4,4a,5,11b-hexahydro-1H-dioxolophenanthridin-6-one
			| image = Pancratistatin.svg
			| width = 200
			<!--Clinical data-->
			| tradename =
			<!--Identifiers-->
⚫	{{Drugbox| verifiedrevid = 416910810
			| CAS_number_Ref = {{cascite|correct| CAS}}
	|
		⚫	| CAS_number = 96281-31-1
⚫	|IUPAC_name = (1R,2S,3S,4S,4aR,11bR)-1,2,3,4,7-pentahydroxy-2,3,4,4a,5,11b-hexahydro-1H-dioxolophenanthridin-6-one
			| UNII_Ref = {{fdacite|correct|FDA}}
	| image=Pann1.gif
	| width= 200		| UNII = 4GUM4B7K5B
		⚫	| PubChem = 441597
⚫	| CAS_number= 96281-31-1
			| ChemSpiderID = 390265
	| ATC_prefix=
	| ATC_suffix=
			<!--Chemical data-->
⚫	| PubChem= 441597
		⚫	| C=14 | H=15 | N=1 | O=8
	| DrugBank=
⚫	| C=14 | H=15 | N=1 | O=8
	| molecular_weight = 325.271
	| smiles = C1OC2=C(O1)C(=C3C(=C2)4((((4O)O)O)O)NC3=O)O		| smiles = C1OC2=C(O1)C(=C3C(=C2)4((((4O)O)O)O)NC3=O)O
			| StdInChI = 1S/C14H15NO8/c16-8-5-3-1-4-13(23-2-22-4)9(17)6(3)14(21)15-7(5)10(18)12(20)11(8)19/h1,5,7-8,10-12,16-20H,2H2,(H,15,21)/t5-,7-,8-,10+,11+,12+/m1/s1
	| metabolism =
			| StdInChIKey = VREZDOWOLGNDPW-ALTGWBOUSA-N
	| elimination_half-life=
	| excretion =
	| pregnancy_category =
	| legal_status =
	| routes_of_administration=
	}}		}}
	'''Pancratistatin''' (PST) is a natural compound initially extracted from ]{{dn}}<ref>Siedlakowski, P.; McLachlan-Burgess, A.; Griffin, C.; Tirumalai, S. S.; McNulty, J.; Pandey, S. Synergy of pancratistatin and tamoxifen on breast cancer cells in inducing apoptosis by targeting mitochondria. Cancer Biol. Ther. 2008, 7, 376-384.</ref>, a Hawaiian native plant, belonging to the family ]<ref name=Shnyder2008>Shnyder, S. D.; Cooper, P. A.; Millington, N. J.; Gill, J. H.; Bibby, M. C. Sodium Pancratistatin 3,4-O-Cyclic Phosphate, a Water-Soluble Synthetic Derivative of Pancratistatin, Is Highly Effective in a Human Colon Tumor Model. J. Nat. Prod. 2008, 71, 321-324.</ref> (AMD). PST has shown some strong anti cancer activities<ref>McLachlan, A.; Kekre, N.; McNulty, J.; Pandey, S. Pancratistatin: a natural anti-cancer compound that targets mitochondria specifically in cancer cells to induce apoptosis. Apoptosis 2005, 10, 619-630.</ref> by displaying potent toxicity against human tumor cells<ref name=Shnyder2008/>. Another distinct feature of PST as an anti cancer secondary metabolite is its ability in inducing ] in cancer cells by targeting their ], while leaving the normal cells unaffected<ref>Griffin, C.; Sharda, N.; Sood, D.; Nair, J.; McNulty, J.; Pandey, S. Selective cytotoxicity of pancratistatin-related natural Amaryllidaceae alkaloids: evaluation of the activity of two new compounds. Cancer Cell Int. 2007, 7, 10.</ref>.		'''Pancratistatin''' ('''PST''') is a natural compound initially extracted from ],<ref name="pmid18075307">{{cite journal | vauthors = Siedlakowski P, McLachlan-Burgess A, Griffin C, Tirumalai SS, McNulty J, Pandey S | title = Synergy of Pancratistatin and Tamoxifen on breast cancer cells in inducing apoptosis by targeting mitochondria | journal = Cancer Biology & Therapy | volume = 7 | issue = 3 | pages = 376–384 | date = March 2008 | pmid = 18075307 | doi = 10.4161/cbt.7.3.5364 | s2cid = 10377367 | doi-access = free }}</ref> a Hawaiian native plant of the family ]<ref name=Shnyder2008>{{cite journal | vauthors = Shnyder SD, Cooper PA, Millington NJ, Gill JH, Bibby MC | title = Sodium pancratistatin 3,4-o-cyclic phosphate, a water-soluble synthetic derivative of pancratistatin, is highly effective in a human colon tumor model | journal = Journal of Natural Products | volume = 71 | issue = 3 | pages = 321–324 | date = March 2008 | pmid = 18154271 | doi = 10.1021/np070477p }}</ref> (AMD).
	==Occurrence==		== Occurrence ==
	Pancratistatin occurs naturally in Hawaiian Spider Lily, a flowering plant within the Amaryllidaceae family. Pancratistatin is mostly found in the bulb tissues of Spider Lilies. It has been shown that the enrichment of atmospheric CO2 can enhance the production of ] secondary metabolites, including Pancratistatin, in these plants<ref>Ziska, L.; Emche, S.; Johnson, E. Alterations in the production and concentration of selected alkaloids as a function of rising atmospheric carbon dioxide and air temperature: implications for ethno-pharmacology. Global Change Biology 2005, 11, 1798-1807</ref>. Pancratistatin can be isolated from the tropical bulbs of ] in the order of 100 to 150 mg/kg when bulbs are obtained from the wild type in Hawaii. However, the compound has to be commercially extracted from field- and greenhouse-grown bulbs or from ]s cultivated, for example, in ], which generate lower levels of Pancratistatin (a maximum of 22 mg/kg) even in the peak month of October. After October, when the bulb becomes dormant, levels of Pancratistatin drop, down to only 4 mg/kg by May. Field-grown bulbs, which show monthly changes in Pancratistatin content, generate somewhat smaller amounts (2–5 mg/kg) compared to those grown in greenhouses cultivated over the same period<ref>Ingrassia, L.; Lefranc, F.; Mathieu, V.; Darro, F.; Kiss, R. Amaryllidaceae isocarbostyril alkaloids and their derivatives as promising antitumor agents. Transl Oncol 2008, 1, 1-13.</ref>. There are about 40 different Spider Lily species worldwide and they are mainly native to the ] of South America.		Pancratistatin occurs naturally in Hawaiian spider lily, a flowering plant within the family ]. Pancratistatin is mostly found in the bulb tissues of spider lilies. It has been shown that the enrichment of atmospheric CO<sub>2</sub> can enhance the production of ] secondary metabolites, including pancratistatin, in these plants.<ref>{{cite journal | vauthors = Ziska LH, Emche SD, Johnson EL, George KA, Reed DR, Sicher RC | title = Alterations in the production and concentration of selected alkaloids as a function of rising atmospheric carbon dioxide and air temperature: implications for ethno-pharmacology. | journal = Global Change Biology | date = October 2005 | volume = 11 | issue = 10 | pages = 1798–1807 | doi = 10.1111/j.1365-2486.2005.001029.x | bibcode = 2005GCBio..11.1798Z | s2cid = 85828604 }}</ref> Pancratistatin can be isolated from the tropical bulbs of '']'' in the order of 100 to 150&nbsp;mg/kg when bulbs are obtained from the wild type in Hawaii. However, the compound has to be commercially extracted from field- and greenhouse-grown bulbs or from ]s cultivated, for example, in ], which generate lower levels of pancratistatin (a maximum of 22&nbsp;mg/kg) even in the peak month of October. After October, when the bulb becomes dormant, levels of pancratistatin drop, down to only 4&nbsp;mg/kg by May. Field-grown bulbs, which show monthly changes in pancratistatin content, generate somewhat smaller amounts (2–5&nbsp;mg/kg) compared to those grown in greenhouses cultivated over the same period.<ref name="pmid18607503">{{cite journal | vauthors = Ingrassia L, Lefranc F, Mathieu V, Darro F, Kiss R | title = Amaryllidaceae isocarbostyril alkaloids and their derivatives as promising antitumor agents | journal = Translational Oncology | volume = 1 | issue = 1 | pages = 1–13 | date = March 2008 | pmid = 18607503 | pmc = 2510759 | doi = 10.1593/tlo.08100 }}</ref> There are about 40 different spider lily species worldwide and they are mainly native to the ] of South America.
	]		]
	]
			== Pharmaceutical research ==
	==Biological activity==
			Pancratistatin is thought to have potential as a basis for the development of new pharmaceuticals,<ref>{{cite journal | vauthors = Nair JJ, Bastida J, Codina C, Viladomat F, van Staden J | title = Alkaloids of the South African Amaryllidaceae: a review | journal = Natural Product Communications | volume = 8 | issue = 9 | pages = 1335–1350 | date = September 2013 | doi = 10.1177/1934578X1300800938 | pmid = 24273880 | s2cid = 196598327 | type = Review | doi-access = free }}</ref> particularly in the field of cancer treatment.<ref>{{cite journal | vauthors = Nair JJ, Bastida J, Viladomat F, van Staden J | title = Cytotoxic agents of the crinane series of amaryllidaceae alkaloids | journal = Natural Product Communications | volume = 7 | issue = 12 | pages = 1677–1688 | date = December 2012 | doi = 10.1177/1934578X1200701234 | pmid = 23413581 | s2cid = 30909906 | type = Review | doi-access = free }}</ref>
	The medicinal and toxic properties of Amaryllidaceae family were first discovered by the ]. They used the oil from ] species for the treatment of ]<ref>Rinner, U.; Hillebrenner, H. L.; Adams, D. R.; Hudlicky, T.; Pettit, G. R. Synthesis and biological activity of some structural modifications of pancratistatin. Bioorg. Med. Chem. Lett. 2004, 14, 2911-2915.</ref>. Consequently, efforts have been made to isolate the active ingredients responsible for this antitumor activity. Some 48 ]s bearing a variety of carbon skeletons have been isolated from Narcissus species<ref>Kekre, N.; Griffin, C.; McNulty, J.; Pandey, S. Pancratistatin causes early activation of caspase-3 and the flipping of phosphatidyl serine followed by rapid apoptosis specifically in human ] cells. Cancer Chemother. Pharmacol. 2005, 56, 29-38.</ref>. One group of these alkaloids does not contain basic nitrogen atoms and is represented by an isoquinolinone structure. The most widely known compounds of this group are ], ] and Pancratistatin (PST)<ref>Pandey, S.; Kekre, N.; Naderi, J.; McNulty, J. Induction of apoptotic cell death specifically in rat and human cancer cells by pancratistatin. Artif Blood Substit Immobil Biotechnol 2005, 33, 279-95.</ref>. The most frequently used term in the literature to describe this group of alkaloids is the ]s<ref>Pettit, G. R.; Gaddamidi, V.; Herald, D. L.; Singh, S. B.; Cragg, G. M.; Schmidt, J. M.; Boettner, F. E.; Williams, M.; Sagawa, Y. Antineoplastic agents, 120. Pancratium littorale. J. Nat. Prod. 1986, 49, 995-1002.</ref>. All these natural products have demonstrated potent ] cytotoxicity against cancer cell lines and potent ] antitumor activity. Therefore, this family as a whole is of interest as a potential source of new lead structures for the development of a future generation of anticancer drugs<ref>Hartwell, JL. Plants used against cancer. Asurvey. Lloydia. 1967,30, 379–436.</ref>.
	PST displays selective potent toxicity against human tumour cells by showing a strong tendency to attack the Mitochondria of the cancer cells while having no influence on normal cells. Studies have shown that Pancratistatin rapidly and efficiently induces apoptosis (programmed cell death) in various types of cancer cell lines, including ], ], ], ], ] and ]. Most importantly, when Pancratistatin was tested for toxicity on peripheral ] from healthy volunteers, there was little or no demonstrable effect on their viability and nuclear morphology, indicating the relative specificity of this compound for cancer cells.
	Some of the recent insights regarding the mode of action of PST include inhibition of the cell cycle from G0/G1 to S phase and powerful anti] activity<ref>Weniger, B; Italiano, L; Beck, JP; Bastida, J; Bergoñon, S; Codina, C; Lobstein, A; Anton, R. Cytotoxic activity of Amaryllidaceae alkaloids. Planta Med. 1995, 61, 77–79</ref>. As mentioned previously, Pancratistatin, unlike other anticancer drugs, discerns between normal and cancerous cells. Pancratistatin does not cause ] double-strand breaks or DNA damage prior to the execution phase of apoptosis in cancer cells. Parallel experimentation with ], a currently used medication for cancer treatment, indicated that VP-16 causes substantial DNA damage in normal non-cancerous blood cells, while Pancratistatin does not cause any DNA double-strand breaks or DNA damage in non-cancerous cells. Pancratistatin induces apoptosis in cancer cells using non-genomic targets, and more importantly does not seem to have any affect non-cancerous cells, presenting a significant platform to develop non-toxic anticancer therapies<ref>Ibn-Ahmed, S; Khaldi, M; Chrétien, F; Chapleur, Y. A short route to enantiomerically pure benzophenanthridone skeleton: synthesis of lactone analogues of narciclasine and lycoricidine. J. Org Chem. 2004, 69,6722–6731.</ref>.
	The capability of Pancratistatin to selectively induce apoptosis in cancer cells is an exciting finding and makes it a suitable anti-cancer agent. Since Pancratistatin shows little structural similarity to any DNA intercalating drug or to paclitaxel derivatives, it appears to be non-genotoxic. Also, Pancratistatin may act upon target while allowing selective induction of apoptosis in cancer cells<ref>Ghosal, S; Singh, S; Kumar, Y; Srivastava, S. Isocarbostyril alkaloids from Haemanthus kalbreyeri. Phytochemistry. 1989, 28, 611–613.</ref>. Recent studies have also shown that the bulbs of ] contain a new ] biosynthetic product designated Pancratistatin that proved to be effective (38-106% life extension at 0.75-12.5 mg/kg dose levels) against the murine P-388 lymphocytic leukemia. Pancratistatin also markedly inhibited (ED50, 0.01 microgram/ml) growth of the P-388 in vitro cell line and in vivo murine M-5076 ovary ] (53-84% life extension at 0.38-3.0 mg/kg)<ref>Pettit, GR; Pettit, GR, III; Groszek, G; Backhaus, RA; Doubek, DL; Barr, R; Meerow, AW. Antineoplastic agents: 301. An investigation of the Amaryllidaceae genus Hymenocallis. J Nat Prod. 1995, 58, 756–759.</ref>.
	==Biosynthesis==		==Biosynthesis==
			]
	Although there may not be a precise elucidation of Pancratistatin biological synthesis, there have been speculations on biosynthesis of ] and ] that are very similar to Pancratistatin in terms of structure. The biosynthesis is accomplished via synthesis from O-] 4 by ] coupling to obtain ] 5 as an intermediate. Subsequent elimination of two carbon atoms and hydroxylations of compound 5 (vittatine) then leads to narciclasine<ref>Fuganti, C; Staunton, J; Battersby, AR. The biosynthesis of narciclasine. J Chem Soc D: Chem Commun. 1971, 19, 1154–1155.</ref>.		Although there may not be a precise elucidation of pancratistatin biological synthesis, there have been speculations on biosynthesis of ] and ] that are very similar to pancratistatin in terms of structure. The biosynthesis is accomplished via synthesis from O-] by ] coupling to obtain ] as an intermediate. Subsequent elimination of two carbon atoms and hydroxylations of vittatine then leads to narciclasine.<ref>{{cite journal | vauthors = Fuganti C, Staunton J, Battersby AR | title = The biosynthesis of narciclasine. | journal = Journal of the Chemical Society D: Chemical Communications | date = 1971 | volume = 19 | issue = 19 | pages = 1154–1155 | doi = 10.1039/C29710001154 }}</ref>
			]]]{{clear}}
	]
	==Total synthesis==		==Total synthesis==
	The first total synthesis of ] (+/-) Pancratistatin was proposed by ] and ], which involved a very complex and long (40 steps) ]. According to both Danishefsky and Joung, there were several weak steps in this synthesis that gave rise to a disappointing low synthetic yield. Amongst the most challenging issues, the Moffatt transposition and theorthoamide problem, which required a blocking maneuver to regiospecifically distinguish the C, hydroxyl group for rearrangement were considered to be the severe cases. However, both Danishevsky and Yon Lee stated that their approach towards the PST total synthesis was not out of merit and believed that their work would interest other medicinal scientists to construct a much more practical and efficient way for PST total synthesis<ref>anishefsky, S.; Lee, J. Y. Total synthesis of (B1)-pancratistatin. J. Am. Chem. Soc. 1989, 111, 4829-37.</ref><ref>Li, M; Wu, A; Zhou, P. A concise synthesis of (+)-pancratistatin using pinitol as a chiral building block. Tetrahedron Lett. 2006, 47, 3707–3710.</ref>.		The first total synthesis <ref>{{cite journal | vauthors = Ghavre M, Froese J, Pour M, Hudlicky T | title = Synthesis of Amaryllidaceae Constituents and Unnatural Derivatives | journal = Angewandte Chemie | volume = 55 | issue = 19 | pages = 5642–5691 | date = May 2016 | pmid = 26969844 | doi = 10.1002/anie.201508227 | doi-access = free }}</ref> of ] (+/-)-pancratistatin was reported by ] and ], which involved a very complex and long (40 steps) ]. According to Danishefsky and Joung, there were several weak steps in this synthesis that gave rise to a disappointing low synthetic yield. Amongst the most challenging issues, the Moffatt transposition and the orthoamide problem, which required a blocking maneuver to regiospecifically distinguish the C, hydroxyl group for rearrangement were considered to be the severe cases. However, both Danishevsky and Yon Lee stated that their approach towards the PST total synthesis was not without merit and believed that their work would interest other medicinal scientists to construct a much more practical and efficient way for PST total synthesis.<ref>{{cite journal | vauthors = Danishefsky S, Lee JY |title=Total synthesis of (.+-.)-pancratistatin |journal=Journal of the American Chemical Society |date=June 1989 |volume=111 |issue=13 |pages=4829–4837 |doi=10.1021/ja00195a039}}</ref><ref>{{cite journal | vauthors = Li M, Wu A, Zhou P | title = A concise synthesis of (+)-pancratistatin using pinitol as a chiral building block. | journal = Tetrahedron Letters | date = May 2006 | volume = 47 | issue = 22 | pages = 3707–3710 | doi = 10.1016/j.tetlet.2006.03.138 }}</ref>
			]
	The work of Danishevsky and Joung provided the foundation for another total synthesis of PST, which was propounded by Li,M. in 2006. This method employed a more sophisticated approach, starting out with the pinitol 30 that its stereocenters are exactly the same as the ones in the C-ring of Pancratistatin<ref>Kim, S.; Ko, H.; Kim, E.; Kim, D. Stereocontrolled total synthesis of pancratistatin. Org Lett. 2002, 4, 1343-5.</ref>. Protection of the diol functions of compound 30 gave compound 31. The free hydroxyl of this was subsequently substituted by an azide to give 32. After removal of the silyl function, a cyclic sulfate was installed to obtain product 33. The Staudinger reaction gave the free amine 34 from azide 33. The coupling reaction between 34 and 35 gave compound 36 with a moderate yield. Methocymethyl protection of both the amide and the free phenol gave compound 37. Treatment of this latter product with t-BuLi followed by addition of cerium chloride gave compound 38. Full deprotection of 38 by BBr3 and methanol afforded pancratistatin 3 in 12 steps from commercially available pinitol with an overall yield of 2.3% 20.
	a: TIPDSCl2, imidazole, DMAP, DMF, 24%. b: DMP, p-TsOH, acetone, 81%. c: PPh3, DEAD, CH3SO3H, CH2Cl2, 0°C to r.t. then NaN3, DMF, 60°C, 72%. d: TBAF, THF, 0°C to r.t., 100%. e: SOCl2, Et3N, CH2Cl2, 0°C. f: NaIO4, RuCl3, aq CH3CN, 87% (more than two steps). g: PPh3, aq THF, 0°C to r.t., 94%. h: Et2O, 35, 0°C, 64%. i: K2CO3, MOMCl,DMF, 84%. j: t-BuLi, CeCl3, ultrasound, THF, -78°C to r.t., 72%. k: BBr3, CH2Cl2, -78°C to 0°C, 1 hour then MeOH, -78°C to 0°C, 2 hours, 52%.		The work of Danishevsky and Joung provided the foundation for another total synthesis of PST, which was propounded by Li, M. in 2006. This method employed a more sophisticated approach, starting out with pinitol that has stereocenters which are exactly the same as the ones in the C-ring of pancratistatin.<ref name="pmid11950358">{{cite journal | vauthors = Kim S, Ko H, Kim E, Kim D | title = Stereocontrolled total synthesis of pancratistatin | journal = Organic Letters | volume = 4 | issue = 8 | pages = 1343–1345 | date = April 2002 | pmid = 11950358 | doi = 10.1021/ol0256419 }}</ref> Protection of the diol functions of compound 30 gave compound 31. The free hydroxyl of this was subsequently substituted by an azide to give 32. After removal of the silyl function, a cyclic sulfate was installed to obtain product 33. The ] gave the free amine 34 from azide 33. The coupling reaction between 34 and 35 gave compound 36 with a moderate yield. Methoxymethyl protection of both the amide and the free phenol gave compound 37. Treatment of this latter product with t-BuLi followed by addition of cerium chloride gave compound 38. Full deprotection of 38 by BBr<sub>3</sub> and methanol afforded pancratistatin 3 in 12 steps from commercially available pinitol with an overall yield of 2.3% 20.<ref>Image gallery: a: TIPDSCl2, imidazole, DMAP, DMF, 24%. b: DMP, p-TsOH, acetone, 81%. c: PPh3, DEAD, CH3SO3H, CH2Cl2, 0&nbsp;°C to r.t. then NaN3, DMF, 60&nbsp;°C, 72%. d: TBAF, THF, 0&nbsp;°C to r.t., 100%. e: SOCl2, Et3N, CH2Cl2, 0&nbsp;°C. f: NaIO4, RuCl3, aq CH3CN, 87% (more than two steps). g: PPh3, aq THF, 0&nbsp;°C to r.t., 94%. h: Et2O, 35, 0&nbsp;°C, 64%. i: K2CO3, MOMCl, DMF, 84%. j: t-BuLi, CeCl3, ultrasound, THF, −78&nbsp;°C to r.t., 72%. k: BBr3, CH2Cl2, −78&nbsp;°C to 0&nbsp;°C, 1 hour then MeOH, −78&nbsp;°C to 0&nbsp;°C, 2 hours, 52%.</ref>
	<gallery>		<gallery>
		⚫	File:Pan4.gif|The abstract of the Stereocontrolled synthesis of pancratistatin
	File:Pan3.gif|Total Synthesis of racemic Pancratistatin
⚫	File:Pan4.gif|The abstract of the Stereocontrolled synthesis of Pancratistatin
	File:Pancratistatin.2.gif|Pancratistatin and Narciclasine
	File:Pancratistatin.1.gif|Streocontrolled synthesis of pancratistatin		File:Pancratistatin.1.gif|Streocontrolled synthesis of pancratistatin
	File:Pancratistatin.3.gif		File:Pancratistatin.3.gif
	File:Pancratistatin.4.gif		File:Pancratistatin.4.gif
	</gallery>		</gallery>
⚫	A very recent approach to a stereocontrolled Pancratistatin synthesis was accomplished by Sanghee Kim from the ], in which claisen rearrangement of dihydropyranethlyene and a cyclic sulfate elimination reaction were employed 21. This reaction has proven to be very highly efficient as it produced an 83% overall synthetis yield. (Proved by H and 13C NMR).
			The most recent and shortest synthesis of pancratistatin was accomplished by David Sarlah and co workers, completing the asymmetric synthesis of (+)-pancratistatin and (+)-7-deoxypancratistatin in 7 and 6 steps respectively.<ref>{{cite journal | vauthors = Hernandez LW, Pospech J, Klöckner U, Bingham TW, Sarlah D | title = Synthesis of (+)-Pancratistatins via Catalytic Desymmetrization of Benzene | journal = Journal of the American Chemical Society | volume = 139 | issue = 44 | pages = 15656–15659 | date = November 2017 | pmid = 29059521 | pmc = 5960067 | doi = 10.1021/jacs.7b10351 }}</ref> The key step of this synthesis was the Nickel catalyzed dearomatization of benzene which directly installed the amine and catachol ring in 98:2 ]. Epoxidation then dihydroxylation of the resulting diene afforded the 4 hydroxyl groups. The synthesis was completed by deprotection of the amine and a Cobalt catalyzed CO insertion to furnish the lactam. (+)-7-deoxypancratistatin can then be directly oxidized in a 62% yield to give (+)-pancratistatin. This synthesis yielded multiple grams of the final product which may be essential in the biological evaluation of pancratistatin and analogues.
⚫	The B ring of the phenanthridone (three membered nitrogen hetrocyclic ring) is formed using the Bischler-Napieralski reaction. The n precursor 3 with its stereocenters in the C ring is stereoselectively synthesized from the cis-disubstituted cyclohexene 4. The presence of unsaturated carbonyl in compound 4 suggested the use of a Claisen rearrangement of 3,4-dihydro-2H-pyranylethylene<ref>Shin, K. J.; Moon, H. R.; George, C.; Marquez, V. E.J. Org.Chem. 2000, 65, 2172.</ref>.
		⚫	A very recent approach to a stereocontrolled pancratistatin synthesis was accomplished by Sanghee Kim from the ], in which ] of dihydropyranethlyene and a cyclic sulfate elimination reaction were employed 21.
⚫	The synthesis starts with the treatment of 6 with excess trimethyl phosphate. This reaction provides phosphate 7 in 97% yield. Using Honer-Wadsworth-Emmons reaction between 7 ands acrolein dimmer 8 in the presence of LHMDS in THF forms (E)-olefin 5 with very high stereoselectivity in 60% yield. Only less than 1% of (Z)-olefin was detected in the final product. The Claisen rearrangement of dihydropyranethylene forms the cis-distributed cyclohexene as a single isomer in 78% yield.
		⚫	The B ring of the phenanthridone (three-membered nitrogen heterocyclic ring) is formed using the Bischler-Napieralski reaction. The n precursor 3 with its stereocenters in the C ring is stereoselectively synthesized from the ''cis''-disubstituted cyclohexene 4. The presence of unsaturated carbonyl in compound 4 suggested the use of a Claisen rearrangement of 3,4-dihydro-2H-pyranylethylene.<ref name="pmid10774042">{{cite journal | vauthors = Shin KJ, Moon HR, George C, Marquez VE | title = Construction of the bicyclohexane template of a conformationally locked carbocyclic adenosine via an olefin keto-carbene cycloaddition | journal = The Journal of Organic Chemistry | volume = 65 | issue = 7 | pages = 2172–8 | date = April 2000 | pmid = 10774042 | doi = 10.1021/jo9917691 }}</ref>
⚫	The next step of the synthesis involves the oxidation of aldehyde of compound 4 using NaClO2 to the corresponding carboxylic acid 9 in 90% yield. Iodolactonization of 9 and subsequent treatment with DBU in refluxing benzene gives rise to the bicyclic lacytone in 78% yield. Mthanolysis of lactone 10 with NaOMe forms a mixture of hydroxyl ester 11 and its C-4a epimer (Pancratistatin numbering). Saponification of the methyl ester 11 with LiOH was followed by a Curtius rearrangement of the resulting acid 12 with diphenylphosphoryl azide in refluxing toluene to afford isocyanate intermediate, which its treatment with NaOMe/MeOH forms the corresponding carbamate 13 in 82% yield.
		⚫	The synthesis starts with the treatment of 6 with excess trimethyl phosphate. This reaction provides phosphate 7 in 97% yield. Using the ] reaction between 7 and ] dimmer 8 in the presence of LHMDS in THF forms (''E'')-olefin 5 with very high stereoselectivity in 60% yield. Only less than 1% of (''Z'')-olefin was detected in the final product. The Claisen rearrangement of dihydropyranethylene forms the cis-distributed cyclohexene as a single isomer in 78% yield.
		⚫	The next step of the synthesis involves the oxidation of aldehyde of compound 4 using NaClO<sub>2</sub> to the corresponding carboxylic acid 9 in 90% yield. ] of 9 and subsequent treatment with DBU in refluxing benzene gives rise to the bicyclic lacytone in 78% yield. Methanolysis of lactone 10 with NaOMe forms a mixture of hydroxyl ester 11 and its C-4a epimer (pancratistatin numbering). Saponification of the methyl ester 11 with LiOH was followed by a ] of the resulting acid 12 with diphenylphosphoryl azide in refluxing toluene to afford an isocyanate intermediate, treatment of which with NaOMe/MeOH forms the corresponding carbamate 13 in 82% yield.
		⚫	The next steps of the synthesis involve the regioselective elimination of the C-3 hydroxyl group and subsequent unsaturation achieved by cyclic sulfate elimination. Diol 16 needs to be treated with thionyl chloride and further oxidation with RuCl<sub>3</sub> provides the cyclic sulfate 17 in 83% yield.<ref>{{cite journal | vauthors = Winkler JD, Kim S, Harrison S, Lewin NE, Blumberg PM |title=Synthesis and Biological Evaluation of Highly Functionalized Analogues of Ingenol |journal=Journal of the American Chemical Society |date=January 1999 |volume=121 |issue=2 |pages=296–300 |doi=10.1021/ja9741842}}</ref> Treatment of cyclic sulfate with DBU yields the desired allylic alcohol 18 (67% yield).
		⚫	Reaction with OsO<sub>4</sub> forms the single isomer 19 in 88% yield. Peracetylation of 19 (77% yield) accompanied by Banwell’s modified ] reaction forms the compound 20 with a small amount of isomer 21 ( 7:1 regioselectivity). The removal of protecting groups with NaOMe/MeOH forms pancratistatin in 83%.
⚫	The next steps of the synthesis involve the regioselevtive elimination of C-3 hydroxyl group and subsequent unsaturation achieved by cyclic sulfate elimination. Diol 16 needs to be treated with thionyl chloride and further oxidation with RuCl3 provides the cyclic sulfate 17 in 83% yield<ref>Winkler, J. D.; Kim, S.; Harrison, S.; Lewin, N. E.; Blumberg, P. M. J.Am. Chem. Soc. 1999, 121, 296.</ref>. Treatment of cyclic sulfate with DBU yields the desired allylic alcohol 18 (67% yield).
			== See also ==
⚫	Reaction with OsO4 forms the single isomerlization 19 in 88% yield. Peracetylation of 19 (77% yield) accompanied by Banwell’s modified Bischler-Napieralski forms the compound 20 with a little amount of isomer 21 ( 7:1 regioselectivity). The removal of protecting groups with NaOMe/MeOH forms Pancratistatin in 83%.
			*]
	== Sources ==		== References ==
	{{reflist}}		{{reflist|30em}}
	]		]
			]
			]